Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:XOMA

XOMA Royalty Q1 2026 Earnings Report

XOMA Royalty logo
$41.31 -0.29 (-0.70%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

XOMA Royalty EPS Results

Actual EPS
N/A
Consensus EPS
$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
N/A
Expected Revenue
$13.87 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

XOMA Royalty Earnings Headlines

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
April 28, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/04/28/10373030.htm
Royalty powerhouse: Ligand and Xoma unite in $739 million deal
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/royalty-powerhouse-ligand-and-xoma-unite-in-739-million-deal/ar-AA21PgfV
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
May 7 at 1:00 AM  |  Banyan Hill Publishing (Ad)
$XOMA stock is up 9% today. Here's what we see in our data.
April 27, 2026  |  quiverquant.comQ
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
April 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-xoma-royalty-corporation-302754588.html
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
April 27, 2026  |  benzinga.comhttps://www.benzinga.com/m-a/26/04/52072759/ligand-bets-on-royalty-growth-with-xoma-buyout-worth-over-700-million
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

View XOMA Royalty Profile
Earnings Tools